Aurinia Announces Appointment of Head of Communications & Advocacy
July 11 2016 - 9:50AM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia”
or the “Company”), a clinical stage pharmaceutical company focused
on the global nephrology market, today announced that it has
appointed Celia Economides to the newly created position of
Associate Vice President, Corporate Communications & Patient
Advocacy.
Ms. Economides will lead the company’s corporate communications,
patient advocacy and investor relations efforts.
Ms. Economides has over 15 years of experience in the life
sciences and biotech industries, spanning communications, finance,
patient advocacy, marketing and clinical development. She most
recently served as a Director in Global Medical Affairs at BioMarin
Pharmaceutical, Inc., where she led both patient advocacy and
competitive intelligence efforts focusing on Duchenne Muscular
Dystrophy. Previously, she led IR & Corporate Communications at
Prosensa, which was acquired by BioMarin in January 2015. Prior to
joining Prosensa, Ms. Economides was Director of IR & Program
Development at the Biotechnology Innovation Organization (BIO),
where she was responsible for BIO’s outreach to the investment
community and working with emerging companies to improve their
communications and partnering activities. She led the program
development at BIO’s annual investor and BD conferences and
provided industry research used in BIO’s policy and advocacy
activities. Prior to BIO, Ms. Economides worked at a healthcare
focused hedge fund and in financial services focusing on the
biotech sector. She began her career working in research at
Columbia University. She holds a Bachelor of Arts (BA) degree from
McGill University and a Master’s in Public Health (MPH) from
Columbia University.
"We welcome Celia as an instrumental addition to our team,” said
Charles Rowland, Aurinia’s CEO. “Celia’s depth and breadth of
experience in the biotech industry will support the company
significantly as we continue our efforts to advance voclosporin and
deliver it to patients globally while building value for our
shareholders.”
"I am pleased to join Aurinia at such a significant moment for
the company and look forward to working alongside a world-class
team with exceptional leadership in bringing treatments to patients
in need,” said Celia Economides. “It is an honor to be able to
share my experience and contribute to the future direction and
growth of a company working so diligently to help patients
suffering from serious and potentially life-threatening
conditions.”
About Aurinia
Aurinia is a clinical stage pharmaceutical company focused on
the global nephrology market. The fully-enrolled Phase 2b AURA-LV
clinical trial is evaluating the efficacy of its lead drug,
voclosporin, as a treatment for active LN. LN is an inflammation of
the kidneys, that if inadequately treated can lead to end-stage
renal disease, making LN a serious and potentially life-threatening
condition.
We seek Safe Harbor.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160711005905/en/
Aurinia Pharmaceuticals Inc.Michael Martin, 250-708-4272Chief
Operating Officermmartin@auriniapharma.comorRenmark Financial
Communications Inc.Barry Mire:
bmire@renmarkfinancial.comLaura Welsh:
lwelsh@renmarkfinancial.comTel: 416-644-2020 or 514-939-3989